On 11–12 September, the REMEDi4ALL consortium met in Ljubljana, Slovenia for our fourth General Assembly Meeting (GAM). The focus was on reviewing progress from the last year and setting priorities for the final two years of the project.
Hosted by the University of Ljubljana, the meeting brought together more than 50 REMEDi4ALL consortium members. Over two days, the agenda covered patient engagement, the Digital Academy, updates from technical work packages and Demonstrator Projects, and new insights on policy, funding, internationalisation, and the REMEDi4ALL platform.
Reflecting on our achievements
Following a welcome from University of Ljubljana’s Irena Mlinarič-Raščan alongside project coordinator EATRIS’ Donald Lo and Anton Ussi, discussions opened with patient engagement and the REMEDi4ALL Digital Academy. Key achievements included the Academy’s launch and the tailored bootcamps for patients and academics held earlier in 2025.
We then looked at technical achievements. These included new publications, the launch of the Expertise Dashboard, and a growing number of verified SOPs on Zenodo.
The afternoon focused on upcoming milestones, including the launch of the REMEDi4ALL partnering portal, developments from our expanding Funders Network, and plans for further engagement during the rest of 2025.
The day closed with a consortium-wide discussion on sustainability: how to ensure REMEDi4ALL continues advancing drug repurposing in Europe and beyond.
Charting the course ahead
Day 2 shifted towards the future. Demonstrator Projects presented their next steps, and the communications team shared plans to maximise impact through ongoing dissemination activities. Looking outwards, consortium members explored how to strengthen partnerships across the global drug repurposing community.
Overall, the fourth REMEDi4ALL General Assembly Meeting was a success, marked by constructive discussions, a shared vision, and a clear sense of the challenges ahead. Consortium members left Ljubljana motivated to continue working together towards our goal: driving forward the repurposing of medicines in Europe.
